Lansoprazole
- Generic Name
- Lansoprazole
- Brand Names
- Prevacid, Prevpac
- Drug Type
- Small Molecule
- Chemical Formula
- C16H14F3N3O2S
- CAS Number
- 103577-45-3
- Unique Ingredient Identifier
- 0K5C5T2QPG
- Background
Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux disease (GERD) along with other patholog...
- Indication
Lansoprazole is used to reduce gastric acid secretion and is approved for short term treatment of active gastric ulcers, active duodenal ulcers, erosive reflux oesophagitis, symptomatic gastroesophageal reflux disease, and non-steroidal anti-inflammatory drug (NSAID) induced gastric and duodenal ulcers. It may be used in the maintenance and healing of sever...
- Associated Conditions
- Duodenal Ulcer, Erosive Esophagitis, Helicobacter Pylori Infection, Symptomatic Gastroesophageal Reflux Disease (sGERD), Ulcer Healing, Zollinger-Ellison Syndrome, Active Duodenal ulcer, Develop NSAID-induced gastric ulcers, Hypersecretory conditions, Maintenance of healing Erosive esophagitis
- Associated Therapies
- -
Elucidation of Acid-Induced Pulmonary Inflammation
- Conditions
- Interventions
- First Posted Date
- 2006-08-09
- Last Posted Date
- 2016-08-05
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 17
- Registration Number
- NCT00361972
- Locations
- 🇺🇸
University of Utah Health Sciences Center, Salt Lake City, Utah, United States
An Open Label pH Comparison of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients
- Conditions
- First Posted Date
- 2006-07-14
- Last Posted Date
- 2009-03-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 80
- Registration Number
- NCT00352261
- Locations
- 🇺🇸
Research Site, Norfolk, Virginia, United States
🇺🇸Research SIte, Springfield, Missouri, United States
Efficacy of Lansoprazole in Chronic Post Nasal Drip
- Conditions
- Interventions
- First Posted Date
- 2006-06-09
- Last Posted Date
- 2012-08-21
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 75
- Registration Number
- NCT00335283
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Vanderbilt Digestive Disease Clinic, TVC, Room 1660, Nashville, Tennessee, United States
Randomized Trial for Pharmacogenomics-based Proton Pump Inhibitor Therapy in Children
- Conditions
- First Posted Date
- 2006-03-07
- Last Posted Date
- 2012-10-11
- Lead Sponsor
- Osaka University
- Registration Number
- NCT00299845
- Locations
- 🇯🇵
Osaka University Hospital, Suita, Osaka, Japan
Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis
- Conditions
- Interventions
- First Posted Date
- 2005-11-10
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 2038
- Registration Number
- NCT00251693
Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis
- Conditions
- Interventions
- First Posted Date
- 2005-11-10
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 2054
- Registration Number
- NCT00251719
Effect of Prevacid on Prostaglandin Levels in Patient With Stress Ulcer
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2013-07-31
- Lead Sponsor
- Emory University
- Target Recruit Count
- 30
- Registration Number
- NCT00239551
- Locations
- 🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
Study of 24-hour Intragastric pH Profiles of Esomeprazole 40 mg and Lansoprazole 30 mg in Healthy Volunteer Subjects
- Conditions
- First Posted Date
- 2005-10-03
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT00230516
- Locations
- 🇺🇸
Research Site, Oklahoma City, Oklahoma, United States
Investigation of the Association Between Nasal Polyposis and Extraesophageal Reflux Disease
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2010-09-22
- Lead Sponsor
- Head and Neck Surgery Associates
- Target Recruit Count
- 20
- Registration Number
- NCT00215787
- Locations
- 🇺🇸
Head and Neck Surgery Associates, Indianapolis, Indiana, United States
A Study to Evaluate the Effect of Lansoprazole on Infants With Gastroesophageal Reflux Disease.
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2010-07-22
- Lead Sponsor
- Takeda
- Target Recruit Count
- 24
- Registration Number
- NCT00220818
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.